GlassScriptPhysician profile
Munjal Patel
NPI 1962866624
$3,861.58
in general payments reported to CMS, 2019-2025
17 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $398 · 2022: $611 · 2023: $618 · 2024: $1,171 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $577.54 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $559.74 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $556.13 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $438.20 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $429.67 | 2021-2025 | Invega Trinza, Invega Sustenna |
| Abbvie INC. | $339.04 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $270.34 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $228.68 | 2022-2024 | Austedo Xr, Uzedy |
| Lundbeck LLC | $167.49 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $79.48 | 2023-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $57.55 | 2024 | Qelbree |
| Sunovion Pharmaceuticals INC. | $38.02 | 2022 | |
| Becton, Dickinson and Company | $27.15 | 2024 | Arista Ah Flexitip |
| Allergan, INC. | $27.09 | 2022 | |
| Idorsia Pharmaceuticals US INC | $24.48 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $21.47 | 2025 | Hetlioz, Fanapt |
| Corium, LLC | $19.51 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munjal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.